Financial Performance - Q2 FY27 (Unaudited)

  • Revenue from operations: ₹4,755 lakhs (₹47.55 crore)
  • Operating Expenses: ₹4,587 lakhs
  • EBITDA: ₹168 lakhs (₹1.68 crore)
  • EBITDA Margin: 4%
  • Depreciation and Amortisation: ₹206 lakhs
  • Finance Cost: ₹113 lakhs
  • Other Income: ₹315 lakhs
  • Profit before exceptional items and tax: ₹164 lakhs
  • Exceptional items: None
  • Profit before tax: ₹164 lakhs
  • Tax expenses: ₹14 lakhs
  • PAT: ₹150 lakhs (₹1.50 crore)
  • PAT Margin: 3%
  • Diluted EPS: ₹0.16

Financial Performance - H1 FY27 (Unaudited)

  • Revenue from operations: ₹10,353 lakhs (₹103.53 crore)
  • Operating Expenses: ₹8,689 lakhs
  • EBITDA: ₹1,664 lakhs (₹16.64 crore)
  • EBITDA Margin: 16%
  • Depreciation and Amortisation: ₹406 lakhs
  • Finance Cost: ₹313 lakhs
  • Other Income: ₹334 lakhs
  • Profit before exceptional items and tax: ₹1,280 lakhs
  • Exceptional items: None
  • Profit before tax: ₹1,280 lakhs
  • Tax credit: ₹456 lakhs
  • PAT: ₹823 lakhs (₹8.23 crore)
  • PAT Margin: 8%
  • Diluted EPS: ₹0.93

Comparative Financial Performance

Q2 FY27 vs Q2 FY26:

  • Revenue increased from ₹1,728 lakhs to ₹4,755 lakhs (175% increase)
  • EBITDA improved from loss of ₹1,110 lakhs to profit of ₹168 lakhs
  • PAT improved from loss of ₹1,428 lakhs to profit of ₹150 lakhs

H1 FY27 vs H1 FY26:

  • Revenue increased from ₹2,955 lakhs to ₹10,353 lakhs (250% increase)
  • EBITDA improved from loss of ₹2,663 lakhs to profit of ₹1,664 lakhs
  • PAT improved from loss of ₹3,132 lakhs to profit of ₹823 lakhs

Balance Sheet Position as of Q2 FY26

  • Total Assets: ₹28,863 lakhs
  • Non-Current Assets: ₹16,809 lakhs (including Property, Plant and Equipment: ₹12,395 lakhs, Right of use assets: ₹706 lakhs, Capital work-in-progress: ₹939 lakhs)
  • Current Assets: ₹12,053 lakhs (including Inventories: ₹6,330 lakhs, Trade Receivable: ₹3,142 lakhs, Cash and Cash Equivalent: ₹150 lakhs)
  • Total Equity: ₹17,174 lakhs (Equity Shared Capital: ₹9,286 lakhs, Other equity: ₹7,888 lakhs)
  • Liabilities: ₹1,338 lakhs (Borrowings: ₹298 lakhs, Lease Liabilities: ₹801 lakhs)
  • Current Liabilities: ₹10,351 lakhs (Borrowings: ₹2,717 lakhs, Lease Liabilities: ₹160 lakhs, Trade Payables: ₹3,588 lakhs)

Business Performance and Outlook

  • Order book stood at ₹137 crore as of September 30, 2026, providing revenue visibility
  • EBITDA impacted by spillover of certain sales scheduled for Q2 into subsequent quarter and higher raw material costs due to geopolitical developments in West Asia
  • Company believes H2 performance is likely to be better than H1 based on current business pipeline and order book
  • Several customer molecules progressing through development and commercialization stages, with potential for additional volumes

Operational Highlights

  • Life Sciences capacity expansion largely on track to enhance ability to support future customer requirements
  • Undertaking debottlenecking initiatives across manufacturing facilities, including installation of downstream equipment
  • Manufacturing facilities underwent planned shutdowns of approximately 10 days during quarter for debottlenecking
  • Pursuing backward integration by developing in-house capabilities for critical raw materials to reduce China dependence
  • Several yield improvement initiatives underway to enhance process efficiencies
  • Successfully completed two major customer audits during quarter (one each in Life Sciences and Specialty Chemicals) with no major observations
  • Awarded EcoVadis Gold Rating for third consecutive year

Business Overview

  • Three business units: Life Sciences & Nucleosides, Specialty Chemicals
  • Export-led business with ~90% of revenue from global geographies (focus on USA & EU)
  • CRDMO services from concept to commercialization
  • Integrated Manufacturing Facility at Khopoli, near Mumbai with 9 multipurpose manufacturing plants
  • 50+ highly qualified scientists specializing in specialty intermediates and bulk chemicals

Quality and Safety Certifications

  • ISO 27001:2022, ISO 14001:2015, ISO 45001:2018, ISO 9001:2015
  • EcoVadis Gold Rating for third consecutive year
  • SBTi and Responsible Care initiated in 2026

Capital Market Information as of September 30, 2026

  • Face Value: ₹10
  • Market Price: ₹154.3
  • 52 Week High/Low: ₹154.3/₹142.65
  • Market Cap: ₹1,432.84 crore
  • Equity Shares Outstanding: 9.28 crore shares